Summary Samples of colorectal carcinoma, adenoma and normal colorectal mucosa were examined for the expression of TGF-P by immunohistochemistry. Immunoreactivity for TGF-P was present in 52 out of a total of 58 samples of normal mucosa examined. In adenomas and carcinomas TGF-P expression was 
TGF-P belongs to a family of polypeptides with diverse biological functions which include the stimulation or inhibition of cell proliferation, enhancement of cell differentiation and stimulation of extracellular matrix formation. TGF-P thus plays a central role in the control of cell growth in normal adult tissues, in embryonic development and also in carcinogenesis (Roberts et al., 1988) . Molecular events which regulate TGF-13 activity are not well understood although the inhibition of epithelial cell proliferation by TGF-P which is an almost universal phenomenon is possibly related to c-myc down-regulation (Barnard et al., 1990) . A number of studies have shown TGF-13 mRNA to be expressed in a variety of human and rodent adult tissues. These studies suggest that TGF-P expression is often associated with the differentiated phenotype; thus in the mouse small bowel mucosa TGF-P expression is maximal at the villus tip (Barnard et al., 1990) . These studies led Barnard et al. (1990) to conclude that TGF-,B may function in the co-ordination of the rapid cell turnover typical of intestinal epithelium. Of further interest has been the report that human colonic adenoma cell lines are more sensitive to the growth inhibitory effects of TGF-P than are colorectal cancer cell lines (Manning et al., 1991) . Furthermore the conversion of an adenoma cell line to a carcinoma cell line is accompanied by a reduced response to the inhibitory effects of TGF-P. It was therefore concluded that reduced responsiveness to the inhibitory effects of TGF-P may be an important event in the loss of growth control in colorectal carcinogenesis (Manning et al., 1991 (Wakefield et al., 1987) . This antibody was raised in rabbits using synthetic peptides corresponding to amino acids 266-278 of human pro-TGF-P3 and has been shown to recognise intracellular TGF-P in tumour cells which are known to express and produce this protein (Flanders et al., 1989) . In our experiments trypsinisation was found to be unnecessary. In each experiment negative controls were examined where the primary antibody was omitted with or without normal rabbit serum. Slides were scored as strongly positive (+), weakly positive (±) or negative (-) .
Results

Mucosa
Positive staining of epithelial cells was present in nine out of ten samples of normal colonic mucosa taken from specimens which did not harbour a tumour. Staining intensity was more marked within surface epithelial cells and became progressively weaker in cells situated more deeply within the crypts (Figure 1) . In 48 out of a total of 58 tumour samples examined mucosa was also included in the tissue sections. Positive staining of mucosal epithelial cells was present in 43 out of these 48 samples (Table I ). In these positive cases within areas which showed no evidence of dysplasia and no features of so-called transitional mucosa (Filipe, 1984) observed with only up to 10% of the cells showing positive staining in some areas. Two of these three tumours were poorly differentiated adenocarcinomas and one was a mucinous carcinoma. Immunostaining overall did not however appear to relate to grade of differentiation (Table II) .
Adenoma
Nine out of the ten adenomas were positive for TGF-P (Table III) . The pattern of staining was similar to that seen in invasive carcinoma in that there was diffuse cytoplasmic staining of all epithelial cells. Within the stroma positive immunoreactivity was observed in macrophages and a few lymphoid cells.
Discussion
The expression of TGF-3 mRNA in cell lines and primary human tumours arising in different tissues is well documented and it appears that by and large tumour levels are enhanced compared to normal tissues (Derynck et al., 1987) . In this study we report the presence of TGF-P in normal large bowel mucosa, colorectal carcinomas and colorectal adenomas.
Immunoreactivity for TGF-P was predominantly present in epithelial cells in the tumours examined which suggest that the site of TGF-P production is largely restricted to the epithelial component. One of the three tumours in which TGF-P showed a patchy distribution was in mucinous carcinoma which was characterised by the presence of large amounts of intercellular mucin and very little stroma. The relative lack of TGF-,B expression in this tumour is in keeping with the ability of TGF-f to stimulate the formation of extracellular matrix. Although TGF-P expression is generally a reflection of cellular differentiation, tumour grade in this study was not associated with any change in TGF-f expression. In normal mucosa TGF-P immunoreactivity showed a striking distribution being present in the upper parts of the crypts which are populated by more differentiated cells, and absent deeply within the crypts in the proliferating cell compartment. This finding is similar to that observed in the rodent large bowel in a different study in which the same antibody was employed (Glick et al., 1991) and conforms to the concept of TGF-P being a feature of the differentiated phenotype. This gradient of staining along the crypt was lost in both dysplastic mucosa and morphologically normal mucosa situated immediately adjacent to tumour. This loss of staining gradient in mucosa showing no significant histological abnormality compared to tumour is of potential interest. It raises the possibility that de-regulation of TGF-P expression occurs as an early event in colorectal carcinogenesis prior to adenoma formation; alternatively it could represent a field effect. To the best of our knowledge this is the first study reporting the presence and differential distribution of TGF-P in human colorectal mucosa.
